FibroGen Inc (NASDAQ: FGEN) on Friday, plunged -9.59% from the previous trading day, before settling in for the closing price of $0.32. Within the past 52 weeks, FGEN’s price has moved between $0.18 and $1.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -35.07% over the past five years. The company achieved an average annual earnings per share of -1.04%. With a float of $94.08 million, this company’s outstanding shares have now reached $101.04 million.
Let’s look at the performance matrix of the company that is accounted for 225 employees. In terms of profitability, gross margin is 57.78%, operating margin of 570.33%, and the pretax margin is 580.39%.
FibroGen Inc (FGEN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of FibroGen Inc is 6.90%, while institutional ownership is 32.67%. The most recent insider transaction that took place on Mar 24 ’25, was worth 50,663. In this transaction CEO of this company bought 145,000 shares at a rate of $0.35, taking the stock ownership to the 543,329 shares. Before that another transaction happened on Mar 20 ’25, when Company’s Director bought 250,000 for $0.35, making the entire transaction worth $88,000. This insider now owns 323,722 shares in total.
FibroGen Inc (FGEN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.06% during the next five years compared to 11.75% growth over the previous five years of trading.
FibroGen Inc (NASDAQ: FGEN) Trading Performance Indicators
FibroGen Inc (FGEN) is currently performing well based on its current performance indicators. A quick ratio of 1.98 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.10, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of FibroGen Inc (FGEN)
FibroGen Inc (NASDAQ: FGEN) saw its 5-day average volume 0.68 million, a negative change from its year-to-date volume of 2.41 million. As of the previous 9 days, the stock’s Stochastic %D was 41.76%. Additionally, its Average True Range was 0.03.
During the past 100 days, FibroGen Inc’s (FGEN) raw stochastic average was set at 8.90%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.70% in the past 14 days, which was lower than the 116.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3096, while its 200-day Moving Average is $0.3942. Nevertheless, the first resistance level for the watch stands at $0.3141 in the near term. At $0.3407, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3539. If the price goes on to break the first support level at $0.2743, it is likely to go to the next support level at $0.2611. Assuming the price breaks the second support level, the third support level stands at $0.2345.
FibroGen Inc (NASDAQ: FGEN) Key Stats
Market capitalization of the company is 29.06 million based on 101,044K outstanding shares. Right now, sales total 29,620 K and income totals -47,580 K. The company made 2,740 K in profit during its latest quarter, and 4,640 K in sales during its previous quarter.